Insider Shareholders with Direct Ownership of Nurix Therapeutics, Inc. (NRIX)
This section provides a comprehensive overview of the insiders with direct ownership of Nurix Therapeutics, Inc. (NRIX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Nurix Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Third Rock Ventures Iii, L.P.
> 10% Shareholder |
5,422,549 | 2,000,000 | 3,422,549 $77.5 Million | 3 |
May 06, 2021
Reduced 24.08%
|
|
Column Group L P
> 10% Shareholder |
6,672,548 | 4,000,000 | 1,394,333 $31.6 Million | 2 |
May 05, 2021
Reduced 58.92%
|
|
Gwenn Hansen
Chief Scientific Officer |
77,402 | 31,328 | 50,670 $1.15 Million | 55 |
Oct 30, 2024
Reduced 6.35%
|
|
Hans Van Houte
Chief Financial Officer |
173,911 | 140,187 | 33,724 $763,511 | 37 |
Nov 01, 2024
Reduced 9.51%
|
|
Christine Ring
Chief Legal Officer |
116,564 | 92,528 | 28,084 $635,821 | 76 |
Nov 04, 2024
Reduced 10.49%
|
|
Stefani Wolff
EVP and COO |
4,810 | 1,802 | 6,113 $138,398 | 10 |
May 01, 2023
Reduced 5.3%
|
|
Pierre Beaurang
Chief Business Officer |
64,330 | 60,000 | 4,330 $98,031 | 15 |
Aug 10, 2021
Reduced 30.27%
|
|
Lori Anne Kunkel
Director |
0 | 54,027 | 0 $0 | 1 |
Jul 17, 2024
Reduced 100.0%
|